SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size ...

Insulet Corporation (PODD) is driving share gains with its prime Omnipod 5 AID (automated insulin delivery) system, which is highly promising for growth in the upcoming quarters. The company continues to expand the platform to new countries with sensor integrations. A strong solvency position also bodes well for the stock. However, the mounting costs of Omnipod 5 production, coupled with its excessive reliance on this offering, raise concerns for the company.In the past year, this Zacks Rank #2 (Buy) stock ...

SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The campaign is from the diaTribe Foundation, a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end diabetes stigma. The Spoonful of Laughter campaign is a national initiative using comedy t ...

Insulet Corp.'s (PODD) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product's market potential. The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% ...

UKRAINE - 2021/06/11: In this photo illustration an Insulet Corporation logo is seen on a smartphone ... [+] and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period. The two stocks that focus on the glucose monitoring ...

Core Insights - Insulet's stock experienced a nearly 11% increase week to date following positive news regarding its insulin pump [1] Product Approval - Insulet announced that its Omnipod 5 Automated Insulin Delivery (AID) System received FDA approval for use in type 2 diabetes patients aged 18 and older [2] - Omnipod 5 is now the only AID device approved by the FDA for both type 1 and type 2 diabetes [3] Market Opportunity - There is a significant addressable market for the Omnipod 5, with over 30 million people in the U.S. suffering from type 2 diabetes, of which approximately 6 million require insulin treatments [4] - Among those requiring insulin, around 2.5 million individuals need multiple daily injections, representing a key target market for Insulet's automated delivery system [4]

Insulet Corp.'s (PODD) groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial. With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes. Insulet's Robust ...

Key Takeaways Shares of Insulet and DexCom, which provide devices for patients with diabetes, were the weakestperforming S&P 500 stocks on Tuesday. The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk of patients developing type 2 diabetes. Insulet and DexCom have been navigating headwinds related to their user growth outlook. Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled ...

Insulet Corporation (PODD) reported second-quarter 2024 adjusted earnings per share (EPS) of 55 cents, up significantly 44.7% from the year-ago period's figure. The bottom line missed the Zacks Consensus Estimate by 3.5%. GAAP EPS was $2.59 compared with the year-ago figure of 39 cents. Q2 Revenues Revenues totaled $488.5 million, which beat the Zacks Consensus Estimate by 5.5%. The top line jumped 23.2% year over year (up 23.4% at the constant exchange rate or CER). CER growth exceeded the company's guidan ...

| --- | --- | --- | --- | --- | |------------------|-------|-------------------|-------|-------| | | | | | | | | | Mattie | | | | | | Podder since 2010 | | | | | | | | | | | | | | | | Insulet | | | | | | Corporation | | | | | | Q2'24 Earnings | | | | | | August 8, 2024 | | | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulat ...